Kornimate/medical-research-clean huggingface dataset:
postpartum hpv vaccination

Conditions: HPV-Related Malignancy

Summary: human papillomavirus (hpv)-related cancers are on the rise in the united states. furthermore, greater than 90% of cervical cancer cases are attributable to hpv, and cervical cancer disproportionately affects women of color in both incidence and mortality. due to low hpv vaccine uptake in the us, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine. the puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. two prior studies have shown that postpartum hpv vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily hispanic populations. however, data show that the immune response in young women is less robust than in adolescents, and no studies have examined immunogenicity in postpartum women specifically. we propose an hpv vaccination pilot study in women who receive postpartum care at university of alabama at birmingham (uab) hospital. we will examine the acceptability, uptake and immunogenicity of the vaccine in the postpartum setting.


Eligibility criteria:
inclusion criteria: * postpartum day 0-4 after vaginal or cesarean delivery at uab hospital exclusion criteria * fetal demise or miscarriage, autoimmune disorder, hiv, hepatitis b/c, chronic steroid use, preeclampsia, non-english speaking
efficacy and tolerability of sti571 (imatinib mesylate) for the treatment of fibrosis in participants with systemic sclerosis

Conditions: Systemic Sclerosis, Scleroderma

Summary: this study investigates the efficacy and safety of sti571 for the treatment of fibrosis in participants with systemic sclerosis. other purposes of the study were to investigate whether sti571 is effective in improving lung functions and other test results called biomarkers. whether sti571 is well-absorbed in systemic sclerosis participants' gut was also investigated by testing the drug level in the blood (pharmacokinetics).


Eligibility criteria:
inclusion criteria: * male and female participants who are equal to or older than 18 years of age and who have early diffuse cutaneous systemic sclerosis (disease duration \< 18 months from the first non-raynaud's symptom) * participants with a modified rodnans skin score (mrss) of at least 20 in the absence of trunk involvement or a mrss of at least 16 in patients with trunk involvement * female patients of childbearing potential practicing two acceptable forms of contraception exclusion criteria: * ssc patients with a mrss greater than 35 * concurrent connective tissue diseases other than systemic sclerosis * significant pre-existing heart, liver, lungs, digestive system, blood and other diseases, cancer * conditions that might mimic the potential side effects of sti571 (blood conditions, liver damage, chronic diarrhea, edema) * concurrent medical therapies (or during last 6 weeks before first dosing) that may potentially influence outcome of the study * allergic to the study medication * pregnancy * breast feeding

Keywords: systemic sclerosis, scleroderma, fibrosis, sti571, imatinib
resection and partial liver segmental transplantation with delayed total hepatectomy

Conditions: Liver Metastases

Summary: rapid is an auxiliary liver transplantation where a small liver partial graft (namely left lateral segments from living or cadaveric donors) is implanted orthotopically after a left hepatectomy of the native liver. subsequently, in order to implement a fast regeneration of the transplanted segments a portal flow diversion is operated in the direction of the future remnant. after obtaining a fast regeneration of the auxiliary future remnant liver the native liver hepatectomy is completed as in a two stage- hepatectomy. peculiar inclusion criteria will be adopted for patient selection with particular reference to the admission of patients with \<3 lung metastases radically treated before transplantation.


Eligibility criteria:
inclusion criteria: * ≥ 18 and \<70 years * performance status, ecog 0-1 * histologically proved adenocarcinoma in colon or rectum * braf wild-type crc on primary tumor or liver metastases * high standard oncological surgical resection of the primary tumor * liver metastases not eligible for curative liver resection confirmed by the validation committee * at least one line (3 months) of chemotherapy * at least 6 months time span from crc resection and date of being listed on the transplantation list. * at least 8 weeks of tumor control: stable disease or partial response according to recist 1.1 criteria * no signs of extra hepatic metastatic disease or local recurrence on ct, mri and pet-ct except patients may have \<3 lung lesions all\<15mm resected or treated by radiotherapy or metastatic hilar nodes treated by resection and without recurrence at 3 months from resection or radiotherapy. * satisfactory blood tests creatinine in normal level, plt \>60.000/mm3, gb\>2500/mm3 * cea stable or in decrease * signed informed consent and expected cooperation of the patients for the treatment and follow up exclusion criteria: * weight loss \>10% the last 6 months * patient bmi \> 30 * participation refusal * general contraindication to lt * other malignancies in the previous 5 years * pregnancy or breast feeding * any reason why, in the opinion of the investigator, the patient should not participate

Keywords: colorectal liver metastases auxiliary liver transplant
role of microvascular insulin resistance and cardiorespiratory fitness diabetes

Conditions: Type 2 Diabetes; Overweight and Obesity

Summary: the goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. in addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.

it is our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance. data from our two research teams suggest that the cardiac and skeletal muscle microvascular dysfunction present in people with type 2 diabetes contributes to limitations in cardiac and skeletal muscle function associated with impaired functional exercise capacity (a major predictor of cv and all-cause mortality). insulin action is a potent predictor of the functional exercise capacity impairment in type 2 diabetes. the exact relationship between insulin action, cardiac and muscle dysfunction, cardiac and skeletal muscle perfusion and decreased functional exercise capacity in type 2 diabetes remains unclear.

Eligibility criteria:
inclusion criteria: * sedentary (defined as less than 1 hour per week of physical activity) * bmi: 25-40 * men and women with and without type 2 diabetes exclusion criteria: * documented cardiovascular disease * uncontrolled hypertension: disease systolic blood pressure (sbp) \> 150, diastolic blood pressure (dbp)\> 110 * obstructive pulmonary disease or asthma * peripheral neuropathy * physical impairment that would limit exercise ability * subjects taking beta blockers, calcium channel blockers, insulin, or thiazolidinediones (tzd) * current or past smoking within the last 1 years * current tobacco use * anemia * control hba1c \> 5.7, t2dm hba1c \> 9 * pregnant, nursing or hormonal therapy (other than contraceptives) * peri or post-menopausal women * type 1 diabetes * hepatic or renal disease.
abemaciclib dose escalation to maintain intensity (ade-mi)

Conditions: Breast Cancer

Summary: this is a post-marketing single arm, phase iv trial in which patients with high-risk early-stage hr+her2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (et) after study intervention, participants will remain on combination abemaciclib + et at the discretion of their treating providers

dose escalation (de) was shown to minimize the rates of grade 3 diarrhea in the setting for her2+ breast cancer. de can improve tolerability for drugs such as abemaciclib. this is a post-marketing single arm, phase iv trial in which patients with high-risk early-stage hr+her2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (et) after study intervention, participants will remain on combination abemaciclib + et at the discretion of their treating providers in this study, the investigators we will test the hypothesis that gradual up-titration of abemaciclib dose over a course of 2-3 weeks will decrease the rate of g3 or worse diarrhea, permitting more patients to remain at the intended dose when evaluated at day 84

Eligibility criteria:
inclusion criteria: * ecog 0-2 * histologically confirmed early-stage hr+her2- breast cancer documented by biopsy who are prescribed adjuvant abemaciclib * able to provide written informed consent and hipaa authorization for release of personal health information, via an approved uic institutional review board (irb) informed consent form and hipaa authorization. * women of childbearing potential must not be pregnant or breast-feeding. a negative serum or urine pregnancy test is required per institutional practice guidelines. * as determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. exclusion criteria: * chronic history of diarrhea * active infection requiring systemic therapy * uncontrolled hiv/aids or active viral hepatitis * pregnant or nursing * any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist. * other major comorbidity as determined by study pi
ultrasound guided erector spinae muscle block in pediatric surgeries

Conditions: Pediatric Hip Surgery

Summary: surgical repair of the hip can be extremely painful and is associated with considerable postoperative pain in children despite the use of systemic opioids. these patients may benefit from neuraxial analgesia in adjunction with general anesthesia.

regional anesthetic techniques have been widely used for pain management in a variety of pediatric surgeries, as they increase the efficiency of postoperative pain control; minimize parenteral opioid requirements, and improve both patient and parent satisfaction as well. the erector spinae muscle plane block (esb) is an evolving regional anesthetic technique gaining popularity in pediatric procedures. erector spinae block is an effective regional anesthesia method as it blocks both somatic and visceral pain by injecting the local anesthetic solution into the inter-fascial space between the transverse process and the erector spinae muscle, it is performed by distributing local anesthetic into several paravertebral spaces. it was reported a successful ultrasound-guided esp block performed at the l4 transverse process level provided postoperative analgesia in adult patients undergoing hip and proximal femur surgeries. caudal block (cb) is a well-established remarkable practice because of its simplicity, safety, and effectiveness. a single-shot caudal block with a local anesthetic agent, such as bupivacaine, is a standard procedure, and analgesia is provided during pediatric orthopedic surgeries in the lower limbs; unfortunately, its action stops early in the postoperative period.

Eligibility criteria:
inclusion criteria: * • asa i and ii, * aged 2-6 years * scheduled for unilateral surgical hip reconstruction under general anaesthesia. exclusion criteria: * children with spinal anomalies, * altered mental status or a history of developmental delay, * infection at the site of injection, * history of allergy to local anaesthetics * history of blood disease or coagulopathy, * patient's guardian refusal to participate in the study
olmesartan medoxomil versus losartan potassium in patients with mild to moderate essential hypertension

Conditions: Essential Hypertension

Summary: the purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.


Eligibility criteria:
inclusion criteria: * mild to moderated essential hypertension (mean seated diastolic blood pressure ≥ 95 mmhg and \<110 mmhg, mean seated systolic blood pressure \< 180 mmhg) * able to give written informed consent exclusion criteria: * known or suspected secondary hypertension * history of chronic hepatic diseases * obstructive hypertrophic cardiomyopathy/clinically significant valvular heart disease * cardiac arrhythmia * unstable angina pectoris * congestive heart insufficiency (new york heart association classification iii-iv) * bilateral renal artery stenosis * isolated renal artery stenosis * post renal transplantation * history of acute myocardial infarction/percutaneous transluminal coronary angioplasty or heart surgery within three months before enrollment * retina bleeding/effusion * insulin dependent diabetes mellitus * uncontrolled non-insulin dependent diabetes mellitus
exploration of the neo-vagina study

Conditions: HIV Infections; Transgender Women

Summary: the current study will explore behavioral, surgical and biological neovaginal and rectal hiv transmission risks and feasibility of collection of blood and ano-genital samples (rectal, genital and neo-vaginal, including urine) for microbiological, immunological and cytological characterization in the context of antiretroviral chemoprophylaxis for the prevention of hiv infection in tgw. this includes the feasibility of home self-collection of ano-genital samples prior to habitual cleansing of the anatomical collection site.

a computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant. the questionnaire can be completed online from any location or at the study clinic and will take about 15-20 minutes.

Eligibility criteria:
inclusion criteria: participants will be recruited through existing social networks among tgw and from the thai red cross anonymous and tangerine clinics providing hiv testing, care and treatment services. tgw attending clinic services will be offered enrollment in the study. particular attention will be paid to offering enrollment to those attending hiv treatment and care services. the current study offers medical evaluation and a range of laboratory testing specific to the health of tgw, which may be of interest and beneficial to them. at the same time, the study may benefit from their participation. exclusion criteria: not tgw
re-linkage to care of patients with hepatitis c

Conditions: Viral Hepatitis C

Summary: the purpose of this study is to identify patients with chronic hepatitis c virus (hcv) who were lost of follow up and relinkage them to hepatitis c care

the investigators will review electronic medical charts to identify patients with hcv diagnosis. next, investigators will evaluate if these patients are routinely followed by liver specialists at the institution. those patients who were lost of follow up will be reached to evaluate their disease and eventually offer them to restart hcv care.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * patients clinically evaluated at least once in the participating medical center * chronic hcv infection exclusion criteria: * there are no exclusion criteria

Keywords: viral infection outcome antiviral therapy
concomitant chemo-radiotherapy in locally advanced non small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: feasibility of pragmatic concomitant chemo-radiotherapy association with 1 cycle of induction chemotherapy, weekly chemo-radiotherapy, and consolidation chemotherapy.


Eligibility criteria:
inclusion criteria: histologically or cytologically confirmed newly diagnosed, untreated, unresectable stage iiia or stage iiib non-small cell lung cancer not scheduled for curative cancer surgery no pleural effusion at least 1 bidimensionally or unidimensionally measurable lesion age 18 years et 70 years; performance status \ 50% write consent exclusion criteria: pregnant or nursing; fertile patients who don't used effective contraception; no other malignancy within past 5 years except inactive carcinoma in situ of the cervix or nonmelanoma skin cancer ; neuropathy grade nci-ctc 2; past thoracic radiotherapy; past chemotherapy, immunotherapy or biologic therapy for non small cell lung cancer ; respiratory deficiency fev1 \< 45% ; hypersensibility to docetaxel or cisplatin; at least 4 weeks since other concurrent investigational agents;

Keywords: carcinoma stage iiia non small cell lung stage iiib non-small-cell lung concomitant chemo-radiotherapy consolidation chemotherapy
immune responses to antigens in non-infectious eye inflammatory diseases

Conditions: Eye Diseases

Summary: this study will collect blood samples from patients with non-infectious eye inflammatory diseases a spectrum of eye disorders that can produce sight-threatening vision loss. the blood will be analyzed for substances that may provide a better understanding of the nature of these disorders, possibly leading to improved treatments. treatment is not offered under this protocol. patients 6 years of age and older with an eye inflammatory disease, including non-infectious uveitis, ocular cicatricial pemphigoid, non-infectious scleritis, episcleritis, stevens johnson syndrome, moorens ulcer, peripheral ulcerative keratitis and keratoconjunctivitis sicca, may be eligible for this study. patients may or may not currently be participating in a treatment trial. participants will have blood drawn through a needle in an arm vein. more samples may be collected if patients enrolled in another study are scheduled for additional visits. no more than 4 teaspoonfuls of blood will be collected at any one time.

ocular inflammatory diseases can lead to visual loss in adults as well as in children. these conditions are usually characterized by repeated exacerbations and remissions. the underlying cause of majority of these conditions is not clear even though an autoimmune mechanism has been implicated. various studies have reported an altered immunological profile in these patients. an underlying immune mechanism has been thought to be playing a role in at least some of the ocular inflammatory diseases. in addition, evidence from literature also suggests inflammatory disease may be an important mechanism leading to age related macular degeneration and diabetic retinopathy, two leading causes for vision loss. however, very little is known about the involvement of immune components in these patients. this protocol proposes to test for proliferative cell mediated and humoral responses against self-antigens from patients with ocular inflammatory diseases, amd and diabetic retinopathy. patients will be recruited from other ongoing protocols. an attempt would be made to find any correlation between the clinical disease and the immunological findings. these findings will not be used for diagnostic nor therapeutic purposes.

Eligibility criteria:
* inclusion criteria: 1. participant is 6 years or older. 2. adult participant is able to understand and sign the informed consent. if the participant is younger than 18 years of age at enrollment, has a parent or legal guardian who is able to understand and sign the consent on their behalf. children must provide assent. 3. patients must have a diagnosis of an ocular inflammatory disease, amd or diabetic retinopathy. exclusion criteria: 1. the presence of non-ocular inflammatory disease. 2. unwilling or unable to provide a blood sample.

Keywords: autoimmunity cell mediated immunity s antigen cell proliferation uveitis cell proliferation assays auto-antibody auto-antigens
safety and efficacy study of a hydrogel, applied following removal of myomas during gynecologic surgery, administered for the prevention/reduction of postoperative adhesion formation

Conditions: Myoma

Summary: the purpose of this study was to determine whether the adhesion prevention gel was safe to use, and was effective for the prevention/reduction of adhesion formation that typically occurs following gynecological surgery to remove myomas

postoperative adhesions are a common medical complication of gynecologic and pelvic surgeries, and are frequently associated with chronic or recurrent pelvic pain, intestinal obstruction and infertility. this randomized, controlled, multicenter, clinical study was designed to evaluate the safety and performance of adhibit™ adhesion prevention gel versus the standard of care for the reduction of postoperative adhesions in subjects undergoing myomectomy via laparotomy or laparoscopy. subjects were scheduled to return within 6-8 weeks after the initial surgical procedure. at that time, a second-look laparoscopy was performed for postoperative adhesion assessment. adhesions were graded using a modified american fertility society (mafs) scoring method.

Eligibility criteria:
inclusion criteria: preoperatively, subjects must have had: * been scheduled for myomectomy via laparotomy or laparoscopy. * agreed to a second-look laparoscopic procedure to assess and lyse any adhesions formed at 6 to 8 weeks following myomectomy. * been \>=18 years of age. * provided voluntary written informed consent. * been willing to comply with all aspects of the treatment and evaluation schedule. intra-operatively, subjects must have had: * had at least one 2 cm incision length on posterior uterine surface, which may include the fundal surface. exclusion criteria: preoperatively, subjects must not have had: * been pregnant. * had a pelvic malignancy. * had acute pelvic inflammatory disease. * had an immune compromised condition. * been a participant in another clinical research study which the investigator believed could interfere with the purpose of this study. * been given corticosteroids intra-operatively or during the course of the postoperative study follow up. intra-operatively, subjects must not have had: * had a pelvic malignancy. * had a pelvic or abdominal infection. * had acute pelvic inflammatory disease. * received any adhesion prevention adjuvants or barriers, or peritoneal instillates containing corticosteroids, nsaids, or dextran.

Keywords: adhesions gynecologic surgery laparoscopy laparotomy polyethylene glycol hydrogel adhesions following gynecologic surgery to remove myomas